On 18 July 2003, Johnson & Johnson filed a patent for bedaquiline, a new antibiotic against Mycobacterium tuberculosis. It was first approved as a medicine in the US in 2012 and is now listed as an essential medicine by the WHO. What should a fair price be for an essential drug? J&J sell bedaquiline at tiered prices around the world: it is more expensive (but easily available) in wealthy countries and cheaper (but hard to come by) where it is most needed. According to Médecins Sans Frontières, in late 2022 it was nearly three times as expensive as it would be in low-income countries if generic forms were available.